Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Extensive Stage Small Cell Lung Carcinoma 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 21cabozantinib 12Specimen Handling 11Ipilimumab 10belzutifan 9pembrolizumab 8Magnetic Resonance Spectroscopy 8CTLA-4 Antigen 5Biopsy 5Axitinib 5lenvatinib 4Sunitinib 4Immunoglobulin G 3Disulfides 3zimberelimab 2tivozanib 2relatlimab 2pazopanib 2palbociclib 2atezolizumab 2aldesleukin 2X-Rays 2Watchful Waiting 2Radiosurgery 2Nephrectomy 2Bevacizumab 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × epacadostat × 30 days × Clear all
NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte Corporation

Phase 3 Completed
129 enrolled 13 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡